Synaffix/LanzaADCsElevation Oncology Inc licences Synaffix B...Elevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) … more ➔
RSRTRNA editingRNA specialist ProQR Therapeutics NV bags...RNA editing specialist ProQR Therapeutics NV has deepened its collaboration with the Rett Syndrome Research Trust, which extented its funding of the preclinical MECP2 inhibitor AX-2402 to US$9.1m to … more ➔
Nobel Prize Outreach / Nanaka AdachiNobel PrizesBreakthroughs honoured: 2024 Nobel PrizesAs part of the 2024 Nobel Prize Week, the prestigious awards have been presented. These include the Nobel Prize in Medicine or Physiology for the discoverers of microRNAs as a new class of regulatory … more ➔
Pixabay- DeltaworksFinancingNoema Pharma AG extends Series B financingSwiss Noema Pharma AG has cashed in a CHF27m extention to its Series B financing that is used to advance four Phase II programmes in neurology. more ➔
Volker Brinkmann / Max Planck Institute for Infection BiologyFinancingCitryll BV raises €85m in Series B finan...Dutch inflammation specialist Citryll BV has raised €85m to push clininal testing of its lead candidate, CIT-013, a bifunctional antibody that prevents the release of neutrophil extracellular traps … more ➔
Dewpoint Therapeutics IncPartnershipsDewpoint Therapeutics and Mitsubishi Tanab...Dewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking … more ➔
Eli Lilly & CompanyObesityUK first country in Europe to reimburse ti...The British NICE has defined the conditions for the reimbursement of Eli Lilly’s obesity blockbuster tirzepatide. This makes the UK the first country in which patients do not have to pay for the drug … more ➔
Biomunex SAT cell engagersFrench Ipsen inks US$610m biobucks deal wi...French Ipsen has exclusively licensed BMX-502, a T-cell engager (TCE) from Biommunex SA, which prevents common problems of TCEs such as cytokine release syndrome and T cell exhaustion by using a specific … more ➔
Resalis Therapeutics srlObesityObesity gene therapy enters Phase I testin...After securing an equity investment from French pharma giant Sanofi, Italian gene therapy company Resalis Therapeutics srl has begun enrolling participants for a Phase I study of its obesity gene therapy, … more ➔
SLASAutomation & Drug ScreeningEuropean Biotechnology and SLAS seal partn...The Society for Laboratory Automation & Screening (SLAS) has selected the European Biotechnology Magazine as its official media partner. more ➔
Synaffix/Lanza
RSRT
Nobel Prize Outreach / Nanaka Adachi
Pixabay- Deltaworks
Volker Brinkmann / Max Planck Institute for Infection Biology
Dewpoint Therapeutics Inc
Eli Lilly & Company
Biomunex SA
Resalis Therapeutics srl
SLAS